%0 Journal Article
%A Moscoso, Alexis
%A Karikari, Thomas K
%A Grothe, Michel J
%A Ashton, Nicholas J
%A Lantero-Rodriguez, Juan
%A Snellman, Anniina
%A Zetterberg, Henrik
%A Blennow, Kaj
%A Schöll, Michael
%T CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.
%D 2022
%U http://hdl.handle.net/10668/20174
%X Clinical trials targeting tau in Alzheimer's disease (AD) need to recruit individuals at risk of tau accumulation. Here, we studied cerebrospinal fluid (CSF) biomarkers and plasma phosphorylated tau (p-tau)181 as predictors of tau accumulation on positron emission tomography (PET) to evaluate implications for trial designs. We included older individuals who had serial tau-PET scans, baseline amyloid beta (Aβ)-PET, and baseline CSF biomarkers (n = 163) or plasma p-tau181 (n = 74). We studied fluid biomarker associations with tau accumulation and estimated trial sample sizes and screening failure reductions by implementing these markers into participant selection for trials. P-tau181 in CSF and plasma predicted tau accumulation (r > 0.36, P  0.36, P  0.37, P  Clinical trials testing tau-targeting therapies may benefit from using fluid biomarkers to recruit individuals at risk of tau aggregation.
%~